2 Healthcare Stocks to Buy Before They Get Bought Out

Abivax: 589.7 million euros (~$697M) in cash (funding into Q4 2027) and obefazimod Phase 3 top-line data due in Q2 (Crohn's Phase 2b top-line due Q4); shares are down ~10% YTD but up >1,900% over the past year amid buyout rumors (Eli Lilly, AstraZeneca). Nektar: rezpegaldesleukin showed >80% of patients maintained ≥75% skin clearance at 36 weeks in Phase 2b; after a $460M capital raise it has >$700M liquidity (funding into 2027) and analysts have price targets of $123–$130 vs current ~ $74, implying meaningful upside; both names are highlighted as potential acquisition targets.

Analysis

These two small-cap biotech stories are being priced more like optionality than operating businesses: equity moves reflect a mix of binary clinical outcomes and takeover optionality rather than predictable revenue streams. That creates asymmetric volatility — implied vols steepen around discrete events while term structure is flatter, meaning you can pay to buy long-dated exposure more cheaply than funding short-dated binary risk.

Second-order competitive effects matter more than headline upside. If an acquirer integrates either program, they will likely re-sequence their existing pipelines and redirect commercial promotion dollars, which can accelerate label defense or crowd out incumbent franchises; conversely, a clinical failure could free up incumbents to expand label claims into adjacent indications. Manufacturing and supply-chain readjustments are subtle but real — small-molecule oral assets (if applicable) pull capacity from different contract manufacturers than injectables, creating stealth winners among CDMOs.

The primary risks are classic: binary trial outcomes, shifting M&A calculus, and sentiment-driven liquidity squeezes. Balance-sheet liquidity reduces near-term financing risk but does not immunize shares from downside on negative data. Practically, trade constructs should therefore separate event gamma (near term) from directional optionality (6–18 months) and explicitly size for a >30% single-event move in either direction.

Key Decisions for Investors

• ABVX: Buy a calendar call spread (buy 9–12 month ATM call, sell 6–8 week shorter-dated ATM call) size 1–2% NAV — captures long-dated upside (acquisition or positive readout) while financing front-month IV that spikes into the event. Target: 3x return if positive corporate outcome within 12 months; max loss limited to premium paid. Monitor IV and unwind 7–10 days before binary events to avoid pin risk.
• NKTR: Go long-stock with a protective put (purchase NKTR shares + 6–9 month 25–30% OTM put). Rationale: preserves upside from potential deal premium or durable phase-2/3 signal while capping downside from an adverse outcome. Position sizing 1–3% NAV; hedge cost expected to be elevated but worthwhile given asymmetric takeover tail.
• Pair trade (event hedge): Long NKTR or ABVX vs short a basket of incumbents (REGN/SNY/ABBV equal-weighted) sized 1:0.5 (long:short) over 6–12 months — this isolates success-as-acquisition upside while neutralizing sector-wide moves. Risk: correlated bid for incumbents; cap exposure to 2% NAV and set stop-loss if pair ratio diverges >30%.
• Volatility structure trade: If front-month IV is >70th percentile vs 6–12 month IV, sell near-term straddles (small size) and buy longer-dated straddles to harvest term premium. Only execute with strict size limits (0.5–1% NAV) and delta-hedge daily; severe one-way moves on data can blow up short front-month exposure so use as a volatility arb, not directional.